Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 5;101(3):340-349.

Incidence of treatment-resistant depression during the first mood depressive episode

Maroua Said  1 , Rania Hosni  2 , Hend Jemli  2 , Yosra Zgueb  2 , Uta Ouali  2 , Haifa Zalila  3 , Fethi Nacef  2 , Rabaa Jomli  2
Affiliations

Incidence of treatment-resistant depression during the first mood depressive episode

Maroua Said et al. Tunis Med. .

Abstract

Introduction: In spite of several approaches and therapeutic measures, treatment-resistant depression (TRD) continues to inflict serious, individual and collective consequences. Therefore, there is a persistent need to scrutinize the concept of TRD in order to adapt the therapeutic strategies.

Aim: To estimate the incidence of TRD in patients with a first major depressive episode (MDD), and study factors associated with resistance.

Methods: A descriptive prospective longitudinal study of outpatients with a first MDD, was conducted. Patients with a history of subthreshold hypomania were excluded. Eligible patients were put on a selective serotonin reuptake inhibitor (SSRI), either fluoxetine or sertraline. Participants were followed regularly until they had a therapeutic response or they met the criteria for TRD.

Results: The study involved 82 adults. The incidence of treatment-resistant depression was 19.4% CI95%=[5.5-33.3]. Among the sociodemographic and clinical factors, family history of psychosis (p=0.038) and chronic respiratory comorbidities (p=0.016) were associated with TRD. The small size of the sample is a potential limitation of this study. Besides, the use of only two SSRIs could influence the results.

Conclusion: In this study, the incidence of TRD was at the lower limit of the rates reported in clinical studies. Clinical factors associated with TRD suggest the relevance of genotype analysis to identify patients with TRD. Furthermore, our results highlight the importance of heeding comorbidities to optimize care. Larger multicenter studies are needed to generalize.

PubMed Disclaimer

Figures

None
Figure 1. Participants through the study phases
See this image and copyright information in PMC

References

    1. Depression [WWW Document] WHO. 2019. [December 30, 2019]. https://www.who.int/news-room/fact-sheets/detail/depression
    1. Richards D. Prevalence and clinical course of depression: a review. Clin Psychol Rev. 2011;31(7):1117–1125. doi: 10.1016/j.cpr.2011.07.004. - DOI - PubMed
    1. Rao D, Xu G, Lu Z, Liang H, Lin K, Tang M. Comparative Study of Cognitive Function Between Treatment-Resistant Depressive Patients and First-Episode Depressive Patients. Neuropsychiatr Dis Treat. 2019;15:3411–3417. doi: 10.2147/NDT.S226405. - DOI - PMC - PubMed
    1. Li G, Fife D, Wang G, et al All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population. Ann Gen Psychiatry. 2019;18:23. doi: 10.1186/s12991-019-0248-0. - DOI - PMC - PubMed
    1. McCrone P, Rost F, Koeser L, et al The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health Abingdon Engl. 2018;27(6):567–573. doi: 10.1080/09638237.2017.1417562. - DOI - PubMed